PMDD and ADHD in Adult Women: A Practical Guide

Premenstrual dysphoric disorder (PMDD) is the severe end of premenstrual symptom worsening. It is a recognised diagnosis in DSM-5-TR and has specific evidence-based treatments. It is also substantially over-represented in women with ADHD. This piece is for women who have ADHD already and are asking whether the late-luteal week they are living through is ordinary cycle variation or something more clinically specific.

This piece works alongside our ADHD and the menstrual cycle piece (which covers ordinary cycle variation) and the co-occurring ADHD and PMDD piece (which covers the clinical overlap in more detail). The focus here is practical: how to recognise it, how to talk about it, what to do.

What PMDD actually is

PMDD is the severe form of premenstrual syndrome. The DSM-5-TR criteria require five or more specific symptoms in the week before menstruation, with at least one of: marked mood lability, marked irritability or anger, marked depressed mood or hopelessness, or marked anxiety ^[1]. The symptoms must consistently appear in the late luteal phase, ease at the start of menstruation, and be absent in the follicular phase. They must cause clinically significant distress or impairment, and they must be confirmed by prospective daily tracking across at least two cycles.

That last point matters. PMDD is not a one-off bad week. It is a recurring, predictable pattern across cycles. The Royal College of Obstetricians and Gynaecologists guideline (Green-top No. 48) is the UK clinical reference for diagnosis and management ^[3]. Prospective tracking is what distinguishes PMDD from ordinary mood variation and from other psychiatric conditions that happen to be present at the same time.

PMDD affects an estimated 3 to 8 percent of women of reproductive age in the general population ^{[1, 4]}. The figure in women with ADHD is materially higher; Dorani and colleagues' 2021 study in the Journal of Psychiatric Research found significantly elevated rates of hormone-related mood symptoms, including PMDD-spectrum presentations, in women with ADHD compared with the general population ^[2].

The PMDD-ADHD overlap

The overlap is large and the reasons make biological sense.

Both ADHD and PMDD involve dopamine and serotonin systems that are sensitive to hormonal modulation. Oestrogen modulates both. The late-luteal oestrogen drop affects dopamine signalling (relevant to ADHD symptoms) and serotonin signalling (relevant to PMDD-pattern mood and irritability). Women with ADHD already have a dopamine system running at a different baseline; the late-luteal hormonal shift hits a more vulnerable substrate ^[5].

Clinically, this often shows up as a late-luteal week that is more severe in women with ADHD than the general PMDD picture would predict. The mood and irritability of PMDD layer on top of the late-luteal worsening of ADHD symptoms; the combination is often harder to live with than either would be alone.

The Young 2020 BMC Psychiatry expert consensus is unambiguous that the PMDD pattern should be specifically asked about in women with ADHD and assessed with the same diagnostic rigour as in any other population ^[5].

How to recognise PMDD versus ordinary cycle variation

Ordinary cycle-related ADHD symptom worsening involves more difficulty with attention, working memory, motivation and emotional reactivity in the late luteal week. It is irritating; it is not usually dangerous.

PMDD adds a layer that goes beyond this:

• Marked mood lability or depressed mood in the late luteal week, often with hopelessness, often with thoughts that life is not worth living, that ease at the start of menstruation.
• Marked irritability or anger that is out of character and disproportionate to triggers, with significant impact on relationships.
• Marked anxiety, sometimes with panic features.
• Profound fatigue that is more than tiredness.
• Sleep disruption that goes beyond ordinary perimenstrual changes.
• Sometimes suicidal ideation specifically in the late luteal week, with no suicidal ideation in the follicular phase.

The last point is the clinical alarm bell. Cyclical suicidal ideation that consistently appears in the late luteal phase and remits at menstruation is one of the most specific markers of PMDD and is treatable. It should not be normalised as ordinary premenstrual symptom.

The practical workflow

The diagnostic workflow for PMDD in the UK ^{[3, 4]}:

1. Prospective daily tracking for two cycles. The Daily Record of Severity of Problems (DRSP) is the standard symptom-tracking tool and is free online via the International Association for Premenstrual Disorders ^[6]. Two cycles minimum; the diagnosis cannot be made retrospectively.
2. GP appointment with the tracking data. Bring the completed records. The GP can make the diagnosis or refer to gynaecology where useful.
3. Treatment decision. Three main evidence-based options.

Treatment options

Three categories of treatment have evidence:

SSRIs. Sertraline, fluoxetine, citalopram and escitalopram are all used for PMDD. The evidence base for SSRIs in PMDD is one of the strongest in any psychiatric condition. Dosing can be continuous or luteal-phase only; the luteal-phase regimen (taken only days 14 to 28) is supported by RCT evidence and is often the preferred starting approach ^{[3, 4]}. For women with ADHD on stimulant medication, the SSRI conversation is one to have with a clinician who can think about both medications together.

Combined oral contraceptives. Specifically the formulations containing drospirenone (Yasmin and equivalents) have evidence in PMDD; the cycle suppression reduces the hormonal swing ^[3]. This option interacts with the ADHD picture in mixed ways; some women find their ADHD symptoms become more even on combined contraception, others find the opposite. See our contraception and ADHD piece for the broader picture.

GnRH analogues with add-back HRT. For severe PMDD that has not responded to first-line options, a gynaecology specialist may consider GnRH analogues, which suppress ovulation entirely. This is a specialist-only treatment and not a first-line conversation. The Royal College guideline covers the indications ^[3].

Lifestyle interventions (regular exercise, stable sleep, reduced caffeine and alcohol in the luteal phase) help around the edges but do not produce meaningful change in moderate to severe PMDD on their own. The evidence base is honest about this; for moderate to severe PMDD, the SSRI or the contraceptive route is the substantive intervention.

What this means in practice

• PMDD is the severe end of premenstrual symptom worsening and is substantially over-represented in women with ADHD.
• The DSM-5-TR criteria require five or more specific symptoms in the late luteal week, confirmed by prospective daily tracking across at least two cycles.
• The clinical alarm bell is cyclical suicidal ideation that appears in the late luteal phase and remits at menstruation; this should not be normalised.
• The UK diagnostic workflow is: track two cycles using the DRSP, take the data to your GP, get a diagnosis and a treatment plan.
• Three evidence-based treatment categories: SSRIs (often luteal-phase only), drospirenone-containing combined oral contraceptives, and (for severe non-responders) specialist GnRH analogue treatment.
• Lifestyle interventions help around the edges but do not substitute for the substantive treatment in moderate to severe PMDD.

When to speak to a professional

Speak to your GP if you have tracked two cycles and the pattern fits PMDD. The DRSP record and a clear "I think this might be PMDD" framing usually gets the conversation started. For cyclical suicidal ideation in the late luteal phase, do not wait for the next cycle to track; this warrants an urgent GP appointment or a mental-health crisis route (NHS 111 mental health option, Samaritans 116 123, 999 / A&E for immediate risk). NeuroFX is an ADHD and autism service and does not provide PMDD-specific treatment, but our adult ADHD assessment for women and prescribing service can think about ADHD medication alongside any PMDD treatment your GP or gynaecologist initiates.

Sources

1. Eisenlohr-Moul T. Premenstrual disorders: a primer and research agenda for psychologists. Clinical Psychology (New York). 2019;72(1):5-17.
2. Dorani F, Bijlenga D, Beekman ATF, van Someren EJW, Kooij JJS. Prevalence of hormone-related mood disorder symptoms in women with ADHD. Journal of Psychiatric Research. 2021;133:10-15.
3. Royal College of Obstetricians and Gynaecologists. Premenstrual syndromes, management (Green-top guideline No. 48). 2017. https://www.rcog.org.uk/
4. NICE Clinical Knowledge Summaries. Premenstrual syndrome. https://cks.nice.org.uk/topics/premenstrual-syndrome/
5. Young S, Adamo N, Asgeirsdottir BB, et al. Females with ADHD: an expert consensus statement taking a lifespan approach. BMC Psychiatry. 2020;20:404.
6. International Association for Premenstrual Disorders. https://iapmd.org/
7. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement. Neuroscience and Biobehavioral Reviews. 2021;128:789-818.